Clinical trial · Observational
A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
A Multi-center, Prospective, Longitudinal Cohort Study to Collect Immunological and Clinical Data on Epstein-Barr Virus (EBV) Reactivation in EBV Seropositive Male and Female Adults Aged 18 to 29 Years
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years. This study will follow a cohort of approximately 100 EBV seropositive adults 18 to 29 years of age in Australia over a 6 or 12-month period. Participants will not receive any study intervention (eg, study treatments, vaccines).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epstein-Barr Virus (EBV) | — | UNRESOLVED | — |
| Healthy Volunteers | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Investigational Procedure | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Healthy participants who are EBV seropositive
- interventionNames
- Procedure: Investigational Procedure
Primary outcomes (2)
- measure
- Number of participants with EBV DNA in blood and saliva at each study visit
- timeFrame
- 6 or 12 months
- measure
- Serology testing indicative of EBV reactivation, measured by anti-VCA IgG/IgM, anti-EBNA-1 IgG and anti-EA IgG at each study visit
- timeFrame
- 6 or 12 months
Secondary outcomes (3)
- measure
- Levels of IgG antibodies binding to EBV antigens, measured at selected time points in a subset of participants
- timeFrame
- 6 or 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 29 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 to 29 years on the day of inclusion * Participants who are healthy as determined by medical evaluation including medical history and physical examination * Participants who are EBV seropositive based on serology testing Exclusion Criteria: Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives, including planning to leave the area of the study before the end of study period The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
References
Publications (0)
Data not yet available